You are here: Industry Insights > FSD Pharma

News List

First hospitalised COVID-19 patient dosed in FSD201 treatment trial europeanpharmaceuticalreview
December 18, 2020
The study will evaluate whether FSD201 is safe and of benefit to hospitalised patients with COVID-19, in combination with standard of care.
FSD Pharma applies to FDA for trial testing FSD201 in COVID-19 patients europeanpharmaceuticalreview
September 03, 2020
The Investigational New Drug Application (IND) is for a Phase II trial evaluating the safety and efficacy of FSD201 (ultramicronized PEA) in hospitalised COVID-19 patients.
FSD Pharma seeks FDA nod for FSD201 phase 2 trial in Covid-19 patients pharmaceutical-business-review
September 02, 2020
FSD Pharma has filed an application with the US Food and Drug Administration (FDA) seeking its approval to launch a phase 2 trial for FSD201 (ultramicronised palmitoylethanolamide, or ultramicronised PEA) in Covid-19 patients.
FSD Receives FDA Approval to Design Trial for COVID-19 Treatment americanpharmaceuticalreview
June 15, 2020
FSD Pharma announced the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus.
FSD Pharma gets FDA nod to design Covid-19 trial with ultramicronised PEA pharmaceutical-business-review
June 05, 2020
FSD Pharma has secured approval from the US Food and Drug Administration (FDA) to design a phase 2a clinical trial to evaluate the efficacy of FSD-201 ...
FSD Pharma Gets Go Ahead for Phase IIa COVID-19 Trial contractpharma
June 04, 2020
To evaluate FSD-201 to treat COVID-19; anti-inflammatory properties aim to avoid the cytokine storm.
FSD Pharma closes deal and acquires Prismic Pharmaceuticals biospectrumasia
July 08, 2019
The FSD Shares issued to the former Prismic shareholders were deposited into escrow at the closing of the Transaction, and are subject to an 18-month staggered release.
Cannabinoid executive switcheroo: FSD Pharma grabs GW’s ex-marketing chief for CEO job fiercepharma
November 27, 2018
As the prescription cannabinoid market heats up, FSD Pharma has tapped some expert help—in the form of a new CEO who previously headed up marketing for rival GW Pharmaceuticals.
FSD Pharma, SciCann Launch clinical research program in Israel biospectrumasia
August 20, 2018
Under the strategic alliance agreement with Mor, FSD Pharma and SciCann will execute a series of rigorous, randomized, placebo-controlled clinical studies to demonstrate the safety and efficacy of the products